Department of Neurology, Xuanwu Hospital (L.W., Bowei Zhang, H.S., W.Z.), Capital Medical University, Beijing, China.
Beijing Institute for Brain Disorders (M.W.), Capital Medical University, Beijing, China.
Stroke. 2023 Sep;54(9):2442-2445. doi: 10.1161/STROKEAHA.123.044060. Epub 2023 Jul 27.
Experimental studies have demonstrated the neuroprotection of ischemic postconditioning (IPostC) in acute ischemic stroke by attenuating ischemia-reperfusion injury. This study aimed to investigate the safety and tolerability of direct IPostC in both a dog model and patients with acute ischemic stroke treated with thrombectomy.
The study involved 2 parts. First, IPostC was induced by repeated balloon inflation and deflation in dogs, where a low-pressure balloon was navigated to the anterior spinal artery, and 4 cycles of 5-minute ischemia followed by 5-minute reperfusion were performed. Vascular injuries were assessed using angiography and vascular tissue specimens. Then, a 3+3 dose-escalation trial was conducted in patients with acute ischemic stroke following successful thrombectomy recanalization. Patients received direct IPostC with ischemia and reperfusion durations in progressive increments of 0, 1, 2, 3, 4, and 5 minutes ×4 cycles. Major adverse responses were defined as vessel perforation, rupture, dissection, reocclusion, severe vasospasm, thrombotic events, and rupture of the balloon.
IPostC was investigated in 4 dogs. No vessel perforation or rupture, dissection, or vasospasm was observed under the angiography. Only 1 vessel experienced mild injury between the intima and the internal elastic membrane detected on a histopathologic slide. Then, 18 patients were recruited. The duration of IPostC was progressively escalated with no major response happened. No patient experienced agitation, discomfort, or other tolerability issues. Five patients (27.8%) experienced any intracranial hemorrhage after thrombectomy, and 1 (5.6%) was symptomatic. At 3-month follow-up, no patient died, and 9 patients (50%) achieved functional independence.
Direct IPostC inducing by 4 cycles of 5-minute ischemia followed by 5-minute reperfusion is safe, feasible, and tolerable in patients with acute ischemic stroke treated with thrombectomy. Further investigations are needed to determine the safety and preliminary efficacy of direct IPostC.
URL: https://www.
gov; Unique identifier: NCT05153655.
实验研究表明,缺血后处理(IPostC)通过减轻缺血再灌注损伤对急性缺血性脑卒中具有神经保护作用。本研究旨在探讨直接 IPostC 在接受血栓切除术治疗的急性缺血性脑卒中犬模型和患者中的安全性和耐受性。
该研究分为两部分。首先,在犬中通过反复球囊充气和放气来诱导 IPostC,将低压球囊导航至前脊髓动脉,并进行 4 个周期的 5 分钟缺血后再灌注。通过血管造影和血管组织标本评估血管损伤。然后,在成功进行血栓切除术再通的急性缺血性脑卒中患者中进行了 3+3 剂量递增试验。患者接受直接 IPostC,缺血和再灌注持续时间逐步递增 0、1、2、3、4 和 5 分钟×4 个周期。主要不良反应定义为血管穿孔、破裂、夹层、再闭塞、严重血管痉挛、血栓形成事件和球囊破裂。
在 4 只犬中研究了 IPostC。血管造影下未见血管穿孔或破裂、夹层或血管痉挛。仅在组织病理学幻灯片上观察到 1 个血管在内膜和内弹性膜之间出现轻度损伤。然后,共招募了 18 名患者。随着 IPostC 时间的逐步延长,未发生主要反应。没有患者出现躁动、不适或其他耐受性问题。5 名患者(27.8%)在血栓切除术后发生任何颅内出血,其中 1 名(5.6%)有症状。在 3 个月的随访中,没有患者死亡,9 名患者(50%)实现了功能独立。
在接受血栓切除术治疗的急性缺血性脑卒中患者中,通过 4 个周期的 5 分钟缺血后再灌注诱导直接 IPostC 是安全、可行和耐受良好的。需要进一步研究来确定直接 IPostC 的安全性和初步疗效。
网址:https://www.clinicaltrials.gov;独特标识符:NCT05153655。